Navigation Links
Dr. Susan Froshauer to join Connecticut bioscience team at CURE
Date:2/12/2013

HARTFORD, Conn., Feb. 12, 2013 /PRNewswire/ -- Peter R. Farina , Ph.D. and David W. Keiser , the two co-chairs of CURE (Connecticut United for Research Excellence), the state bioscience organization, today released the following statement about organizational changes at CURE.

After ten years at the helm, Paul Pescatello , the current President and CEO of CURE, has decided to step back from that role so that he can dedicate some additional time to private business ventures and other non-life sciences policy issues. Paul has made great strides for CURE and so we are pleased to report that he has agreed to continue to coordinate our government relations efforts as Chair of the CURE BioScience Growth Council and as a CURE Board and Executive Committee member. This arrangement will allow Paul to bring even greater focus and depth to CURE's life sciences advocacy.

The state has recently increased its investment in the life sciences and in entrepreneurship. For example, it has invited The Jackson Laboratory to develop a genomic medicine facility in Farmington and created Connecticut's Innovation Ecosystem, a public-private partnership, with hubs in Hartford, New Haven, Stamford and Storrs, to support high-value technology-based start-up and stage 2 companies. Furthermore, Governor Malloy has proposed a new $200 million Bioscience Innovation Act and announced a $1.5 million investment in UConn to support STEM (Science, Technology, Engineering and Math) education activities.

CURE seeks to strengthen and enhance its mission to support these efforts. To do so most effectively, and build on Paul's success, it is our great pleasure to announce that a good friend of the Connecticut life sciences community, Dr. Susan Froshauer , has agreed to assume the position of Chief Executive Officer and President of CURE, effective April 1. Susan is well-known to the CURE community and has a wealth of experience that makes her an ideal choice to lead the organization.

Susan is an experienced scientist, mentor, entrepreneur and investor with skill at connecting academic expertise and technology with the commercial sector. She is currently Director of the Technology Exchange Portal at the University of Connecticut's Office of Economic Development.  In this role Susan assists Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connects ideas with business expertise, business plans with investors and industry with scholars.

Until 2010, Susan served as President and CEO of Rib-X Pharmaceuticals, which she co-founded in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing and government grants and built a robust pipeline of antibiotics to treat serious hospital infections. Prior to Rib-X, Susan served as a member of Pfizer's Strategic Alliance Group where she was key to the creation of a $200 million investment portfolio that transformed the Pfizer global research and development strategy, helping the company identify new resources for drug discovery.

Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B. A. from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child 's Fellow.

Susan will initially focus on expanding the CURE network, fostering connectivity among members, educators, investors and entrepreneurs, helping to build the bridges necessary to transform cutting edge bioscience research into funded, sustainable start-up biotechs as well as fortifying CURE's commitment to education.

Please join us in welcoming Susan and thanking Paul for his decade of CURE leadership. The combined team of Susan and Paul will strengthen and enhance CURE and its work on behalf of CURE members.

Photo of Paul Pescatello : http://curenet.org/photos/PaulPescatello.jpg
Photo of Dr. Susan Froshauer : http://curenet.org/photos/Susan Froshauer.jpg

Contact:
Bill Kelly
HarveyMalis Communications LLC
203-375-2696


'/>"/>
SOURCE CURE (Connecticut United for Research Excellence)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Connecticut Radiology Group Leverages MedInformatix RIS to Achieve Stage 1 Meaningful Use Objectives
2. Medbox, Inc. Rides a Wave of Local Media Support in Connecticut
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
5. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
6. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
7. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
8. Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Congresswoman Barbara Lee Visits Tethys Bioscience
11. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Ky. , Feb. 12, 2016 /PRNewswire/ ... has completed a $47.1 million Series D ... Cormorant Asset Management, Hillhouse Capital Group and ... Morningside Venture Investments, AJU IB Investment, and ... be used to further advance clinical trials ...
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... and improving the lives of pets, today announced the ... the New Animal Drug Application (NADA) for Zimeta™ (dipyrone ... study (KB0120) of Zimeta for the control of pyrexia ... --> --> The ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises ... businesses. , The increasingly modern world of instantaneous consumption proves very convenient for ... sources such as oil and coal, which pollutes our air, water, and soil. It ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage of ... perfection, go out of their way to be romantic, and may exaggerate a strength ... at any online dating profile. , A recent study from Queendom.com , ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... VA (PRWEB) , ... February 12, 2016 , ... ... Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... in the life cycle of pharmaceutical products, garnering increased attention from all stakeholders ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology ... for the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards ... Executive Forum and Awards Gala on March 15, 2016 at the Westin Peachtree ...
Breaking Medicine News(10 mins):